Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacists Stall Turkey's Launch Of Regulated Consumer Health Market

Executive Summary

Turkish regulators published a list of 241 products, based on 62 ingredients, selected to become available nonprescription but withdrew it after pharmacists argued that consumers in the country typically are not knowledgeable about health care issues and might buy the wrong drug product without a doctor’s advice.

You may also be interested in...



Turkey Poised To Stretch Consumer Health Market; Rigid On Ads, Access

Some 80 pharmaceutical and vitamin products already are available nonprescription in parts of Turkey, but a proposal in development for almost two years would be the country's first regulation for sales of consumer health care products.

Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles

The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems  ̶  and the solutions  ̶  to Medtech Insight.

A Bright Moment At Last In Turkish Medtech Debt Payments Saga

Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel